From professional translators, enterprises, web pages and freely available translation repositories.
pde
fosfodiesteraser
Last Update: 2014-12-09
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
pde 5 inhibitors
pde 5-hemmere
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
concomitant use of pde-5
samtidig bruk av pde-5
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
of the pde-5 inhibitor to
pde-5 hemmeren for å få
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
anagrelide is an inhibitor of pde iii.
anagrelid er en pde iii-hemmer.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
phosphodiesterase type 5 (pde-5) inhibitors
hemmere av fosfodiesterase type 5 (pde 5)
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
pde-5 inhibitors are primarily metabolised by cyp3a.
pde 5-hemmere metaboliseres hovedsakelig av cyp3a.
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
anagrelide is an inhibitor of cyclic amp phosphodiesterase iii (pde iii).
anagrelid er en syklisk amp fosfodiesterase iii (pde iii)-hemmer.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
pde-5 inhibitors for the treatment of erectile dysfunction (ed)
pde-5 hemmere for behandling av erektil dysfunksjon (ed)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in clinical studies, riociguat has shown to augment the hypotensive effects of pde 5 inhibitors.
i kliniske studier har riociguat vist seg å øke pde5-hemmeres hypotensive effekt.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
700-fold over pde 2, 3, 4, 7, 8, 9, 10 and 11.
700 ganger høyere enn for pde 2, 3, 4, 7, 8, 9, 10 og 11.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
these adverse drug reactions are expected based on the pharmacology of anagrelide (inhibition of pde iii).
disse legemiddelbivirkningene er forventet, basert på farmakologien til anagrelid (hemming av pde iii).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
concomitant use of anagrelide with other pde iii inhibitors such as milrinone, amrinone, enoximone, olprinone and cilostazol is not recommended.
samtidig bruk av anagrelid med andre pde iii-hemmere, f.eks. milrinon, amrinon, enoximon, olprinon og cilostazol anbefales ikke.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
caution is recommended during concomitant use of kuvan with all medicinal products that cause vasodilation, including those administered topically, by affecting nitric oxide (no) metabolism or action including classical no donors (e.g. glyceryl trinitrate (gtn), isosorbide dinitrate (isdn), sodium nitroprusside (snp), molsidomin), phosphodiesterase type 5 (pde-5) inhibitors and minoxidil.
forsiktighet er anbefalt ved samtidig bruk av kuvan og alle legemidler som kan gi vasodilatasjon, inkludert de som administreres topikalt, ved å påvirke nitrogenoksid (no) metabolismen eller -funksjonen, inkludert klassiske no-donorer (f. eks glyceryltrinitrat (gtn), isosorbiddinitrat (isdn), kalsiumnitroprussid (snp), molsidomin), fosfodiesterase type 5 (pde-5) hemmere og minoksidil.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: